Latest News

New intravenous formulation GTx-104 shows promise in improving brain health outcomes for aSAH patients, offering safer treatment options for pharmacists.

Hercessi shows promising efficacy and safety in treating HER2+ metastatic breast cancer (MBC), with no significant risks from switching from Herceptin.

New research raises questions regarding the efficacy of nirmatrelvir-ritonavir in preventing long COVID, with limited protection found among older adults and high-risk individuals.

Pneumococcal 21-valent conjugate vaccine (PCV21) was found to be immunogenic and safe in individuals living with HIV, providing significant indications of efficacy in immunocompromised patients.

Pharmacists navigate rapid oncology drug therapy changes, enhancing patient care through education, biomarker insights, and tailored counseling strategies.

Pharmacists contribute across direct patient care and education, adherence, and facilitating access.

Pharmacists are central to patient education, adherence monitoring, and collaboration within multidisciplinary teams.

Older adults face heightened risks from RSV due to declining immunity and chronic conditions, making vaccination crucial for prevention and health.

The FDA linked cerebral folate deficiency to developmental delays with autistic features, although research remains ongoing.

However, experts say that a causal relationship between acetaminophen and autism has not been established.

New clinical trial results reveal that giredestrant combined with everolimus significantly enhances progression-free survival in patients with advanced ER-positive breast cancer.

Individualized interventions, medication reconciliation, and postdischarge follow-up help reduce errors and elevate care continuity.

New research reveals how BCMA mutations in multiple myeloma affect the efficacy of immunotherapy drugs, guiding treatment decisions for patients.

Explore the evolving landscape of biological medicine, focusing on quality standards and innovations in cell and gene therapies for chronic diseases.

Belantamab mafodotin with bortezomib shows promising survival benefits for lenalidomide-refractory multiple myeloma patients.

Careful selection of pharmacotherapy and close monitoring are crucial to ensuring safety and efficacy.

The indication is for the treatment of adult and pediatric patients who weigh at least 30 kg.

Pharmacists are key to closing care gaps and supporting long-term recovery.

Guselkumab becomes the first and only IL-23 inhibitor with a fully subcutaneous induction regimen for adults with ulcerative colitis.

Idecabtagene vicleucel shows a lower infection risk than other BCMA therapies for multiple myeloma.